Investment analysts at Robert W. Baird assumed coverage on shares of Contineum Therapeutics (NASDAQ:CTNM – Get Free Report) in a note issued to investors on Tuesday, MarketBeat Ratings reports. The brokerage set an “outperform” rating and a $32.00 price target on the stock. Robert W. Baird’s price objective would suggest a potential upside of 96.80% from the stock’s current price.
Separately, Royal Bank of Canada boosted their price target on Contineum Therapeutics from $30.00 to $32.00 and gave the company an “outperform” rating in a report on Wednesday, August 14th. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $29.50.
View Our Latest Report on Contineum Therapeutics
Contineum Therapeutics Trading Down 0.1 %
Contineum Therapeutics (NASDAQ:CTNM – Get Free Report) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.02). Analysts predict that Contineum Therapeutics will post -2.04 EPS for the current year.
Hedge Funds Weigh In On Contineum Therapeutics
A number of large investors have recently bought and sold shares of the business. Johnson & Johnson acquired a new stake in shares of Contineum Therapeutics during the 2nd quarter worth approximately $34,853,000. Perceptive Advisors LLC acquired a new stake in Contineum Therapeutics in the second quarter worth $27,589,000. Versant Venture Management LLC bought a new stake in Contineum Therapeutics in the second quarter valued at $16,169,000. Squarepoint Ops LLC acquired a new position in shares of Contineum Therapeutics during the second quarter valued at $2,642,000. Finally, Driehaus Capital Management LLC bought a new position in shares of Contineum Therapeutics during the second quarter worth about $1,174,000.
Contineum Therapeutics Company Profile
Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).
Further Reading
- Five stocks we like better than Contineum Therapeutics
- What is the S&P 500 and How It is Distinct from Other Indexes
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- Using the MarketBeat Stock Split Calculator
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for Contineum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Contineum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.